Travere Therapeutics, Inc., (TVTX) and CSL Vifor Wednesday said the European Commission has granted conditional marketing authorization for Filspari for the treatment of adults with primary IgA nephropathy (IgAN), a rare kidney disorder.
The European Commission's decision follows positive opinion of the Committee for Medicinal Products for Human Use (CHMP) in February this year, based on results from the Phase 3 PROTECT Study of Filspari in IgAN.
CSL Vifor, which possesses exclusive commercialization rights for Filspari in Europe, Australia and New Zealand, expects to launch the drug in the second half of 2024.
In February last year, Filspari was granted accelerated approval by the US Food and Drug Administration to reduce proteinuria in adults with IgAN.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.